MX355371B - Composiciones farmacéuticas combinadas y método de tratamiento del vértigo, la cinetosis y la distonía vegetativa-vascular. - Google Patents

Composiciones farmacéuticas combinadas y método de tratamiento del vértigo, la cinetosis y la distonía vegetativa-vascular.

Info

Publication number
MX355371B
MX355371B MX2013000805A MX2013000805A MX355371B MX 355371 B MX355371 B MX 355371B MX 2013000805 A MX2013000805 A MX 2013000805A MX 2013000805 A MX2013000805 A MX 2013000805A MX 355371 B MX355371 B MX 355371B
Authority
MX
Mexico
Prior art keywords
vegetative
treatment
pharmaceutical compositions
kinetosis
vertigo
Prior art date
Application number
MX2013000805A
Other languages
English (en)
Other versions
MX2013000805A (es
Inventor
Oleg Iliich Epshtein
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX355371(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130356/15A external-priority patent/RU2542453C2/ru
Priority claimed from RU2010130353/15A external-priority patent/RU2542445C2/ru
Priority claimed from RU2011127052/15A external-priority patent/RU2503462C2/ru
Priority claimed from RU2011127058/15A external-priority patent/RU2536232C2/ru
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of MX2013000805A publication Critical patent/MX2013000805A/es
Publication of MX355371B publication Critical patent/MX355371B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)

Abstract

La presente invención se refiere a una composición homeopática que comprende a) una forma activada-potenciada de anticuerpo contra la proteína S-100 específica del cerebro y b) una forma activada-potenciada de anticuerpos contra la NOS endotelial.
MX2013000805A 2010-07-21 2011-07-15 Composiciones farmacéuticas combinadas y método de tratamiento del vértigo, la cinetosis y la distonía vegetativa-vascular. MX355371B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
RU2010130356/15A RU2542453C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство и способ лечения вегето-сосудистой дистонии, синдрома головокружения различного генеза и кинетозов
RU2010130353/15A RU2542445C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2011127052/15A RU2503462C2 (ru) 2011-07-01 2011-07-01 Способ лечения головокружения различного генеза, кинетозов и вегето-сосудистой дистонии (варианты) и лекарственное средство
RU2011127058/15A RU2536232C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
PCT/IB2011/002378 WO2012010974A2 (en) 2010-07-21 2011-07-15 Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia

Publications (2)

Publication Number Publication Date
MX2013000805A MX2013000805A (es) 2013-10-28
MX355371B true MX355371B (es) 2018-04-17

Family

ID=44899157

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000805A MX355371B (es) 2010-07-21 2011-07-15 Composiciones farmacéuticas combinadas y método de tratamiento del vértigo, la cinetosis y la distonía vegetativa-vascular.

Country Status (23)

Country Link
US (1) US20130058981A1 (es)
EP (1) EP2596018A2 (es)
JP (2) JP2013536174A (es)
KR (1) KR20130102542A (es)
CN (1) CN103124741A (es)
AR (1) AR082314A1 (es)
AU (1) AU2011281248B2 (es)
BR (1) BR112013001296A2 (es)
CA (1) CA2805985A1 (es)
CL (1) CL2013000201A1 (es)
DE (1) DE112011102397T5 (es)
EA (1) EA029998B1 (es)
ES (1) ES2446643R1 (es)
FR (1) FR2962910A1 (es)
GB (1) GB2496342B (es)
IL (1) IL224336A (es)
IT (1) ITTO20110630A1 (es)
MX (1) MX355371B (es)
NZ (1) NZ606988A (es)
PE (1) PE20131065A1 (es)
PH (1) PH12013500141A1 (es)
SG (2) SG187160A1 (es)
WO (1) WO2012010974A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
EP2593474A2 (en) 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
CZ2013105A3 (cs) * 2010-07-15 2013-05-22 Iliich Epshtein@Oleg Zpusob zvýsení úcinku aktivované potencované formy protilátky
DE112011102349T5 (de) 2010-07-15 2013-04-18 Oleg Iliich Epshtein Pharmazeutische Zusammensetzung und Behandlungsverfahren
AU2011281247B2 (en) 2010-07-21 2015-07-30 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
WO2012010970A2 (en) 2010-07-21 2012-01-26 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
US20130058982A1 (en) * 2010-07-21 2013-03-07 Oleg Iliich Epshtein Method of treating Alzheimer's disease
BR112013001299A2 (pt) * 2010-07-21 2017-11-21 Lliich Epshtein Oleg composições farmacêuticas e respectivo uso e métodos de tratamento de diabetes e doenças correlatas em paciente humano
CN103154030A (zh) * 2010-08-06 2013-06-12 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对传染性疾病进行治疗和预防的方法
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2113230C1 (ru) 1996-04-03 1998-06-20 Ильчиков Михаил Захарович Седативное лекарственное средство "авиаморе"
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
US5849528A (en) * 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
AU2002258518A1 (en) * 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
RU2201255C1 (ru) * 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
JP2006516089A (ja) * 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
TWI345470B (en) 2003-03-14 2011-07-21 Nutrition Res Inc Homeopathic formulations useful for treating pain and/or inflammation
EP2593474A2 (en) * 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
DE112011102349T5 (de) * 2010-07-15 2013-04-18 Oleg Iliich Epshtein Pharmazeutische Zusammensetzung und Behandlungsverfahren
CZ2013105A3 (cs) * 2010-07-15 2013-05-22 Iliich Epshtein@Oleg Zpusob zvýsení úcinku aktivované potencované formy protilátky
WO2012010970A2 (en) * 2010-07-21 2012-01-26 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
AU2011281247B2 (en) * 2010-07-21 2015-07-30 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
FR2962914A1 (fr) * 2010-07-21 2012-01-27 Oleg Iliich Epshtein Composition pharmaceutique destinee a etre utilisee dans un procede pour traiter les maladies organiques du systeme nerveux, le syndrome psycho-organique et l'encephalopathie
US20130058982A1 (en) * 2010-07-21 2013-03-07 Oleg Iliich Epshtein Method of treating Alzheimer's disease
BR112013001299A2 (pt) * 2010-07-21 2017-11-21 Lliich Epshtein Oleg composições farmacêuticas e respectivo uso e métodos de tratamento de diabetes e doenças correlatas em paciente humano

Also Published As

Publication number Publication date
CL2013000201A1 (es) 2015-01-23
GB201302925D0 (en) 2013-04-03
EA029998B1 (ru) 2018-06-29
PH12013500141A1 (en) 2013-03-11
ES2446643R1 (es) 2015-03-06
JP2016199571A (ja) 2016-12-01
SG10201505676RA (en) 2015-08-28
EP2596018A2 (en) 2013-05-29
SG187160A1 (en) 2013-02-28
WO2012010974A2 (en) 2012-01-26
AU2011281248B2 (en) 2017-02-02
IL224336A (en) 2017-06-29
MX2013000805A (es) 2013-10-28
CN103124741A (zh) 2013-05-29
CA2805985A1 (en) 2012-01-26
WO2012010974A8 (en) 2013-04-25
NZ606988A (en) 2015-08-28
GB2496342B (en) 2017-12-06
ES2446643A2 (es) 2014-03-10
US20130058981A1 (en) 2013-03-07
GB2496342A (en) 2013-05-08
ITTO20110630A1 (it) 2012-01-22
JP2013536174A (ja) 2013-09-19
PE20131065A1 (es) 2013-09-23
AU2011281248A1 (en) 2013-03-14
FR2962910A1 (fr) 2012-01-27
AR082314A1 (es) 2012-11-28
EA201300127A1 (ru) 2013-12-30
WO2012010974A3 (en) 2012-04-19
KR20130102542A (ko) 2013-09-17
DE112011102397T5 (de) 2013-05-08
BR112013001296A2 (pt) 2017-12-19

Similar Documents

Publication Publication Date Title
PH12013500141A1 (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
EA201590388A1 (ru) Способы лечения таупатии
PH12015500390A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
MX2012007684A (es) Modificacion covalente ligando dirigida de proteina.
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
PH12016500275A1 (en) Antibodies
UA107836C2 (uk) Метод лікування хвороби альцгеймера
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
WO2012014078A3 (en) Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy
AU2014286128B2 (en) Human anti-IL-32 antibodies
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
TN2011000041A1 (en) Compositions and methods for antibodies targeting complement protein c5

Legal Events

Date Code Title Description
FG Grant or registration